Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 38Gastrointestinal 38Genitourinary 28Breast 20Gynecologic 19Head & Neck 17CNS 11Endocrine 7Dermatologic 7Sarcoma 4NET 4Lymphoid 4Tumor-Agnostic 3Other hematologic neoplasm 3Other neoplasm 2Myeloid 2Plasma cell 1Other solid neoplasm 1Other 1

Conditions

Advanced Solid Tumors 432Advanced Solid Tumor 352Solid Tumor 305Solid Tumors 246Mesothelioma 115Solid Tumor, Adult 76Mesothelioma, Malignant 72Carcinoma, Non-Small-Cell Lung 66Ovarian Neoplasms 47Melanoma 42Carcinoma, Renal Cell 37Colorectal Neoplasms 34Advanced or Metastatic Solid Tumors 32Uterine Cervical Neoplasms 31Stomach Neoplasms 31Solid Tumours 31Esophageal Neoplasms 30Neoplasms 27Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Advanced Malignant Solid Tumors 25Triple Negative Breast Neoplasms 24Lung Neoplasms 24Small Cell Lung Carcinoma 23Advanced Solid Tumours 23Sarcoma 21Neoplasm Metastasis 21Advanced Malignant Solid Tumor 21Locally Advanced or Metastatic Solid Tumors 20

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Site × Other solid neoplasm × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡